Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 4,300 shares at $8.07 ($35K) on 2014-07-03, disclosed to the SEC on 2014-07-07.
Scheduled sale ($35k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.07 | 3,100 | $25K | 72.1% |
| 2 | $8.07 | 1,200 | $10K | 27.9% |
| Total | $8.07 avg | 4,300 | $35K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |